This builds upon its initial approval in May 2024 for adults aged 60 years and older, which makes mRESVIA the second approved ...

Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the US Food and Drug Administration (FDA) ...

NEW YORK CITY, NEW YORK / ACCESS Newswire / June 14, 2025 / New to The Street (NTTS) and High Performance Battery Technology ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

In other developments, the ECDC today reported a slow rise in COVID activity in the Europe, which may partly reflect waning ...

The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on ...